Reviva Pharmaceuticals Holdings, Inc. (RVPH): Operating Cash Flow
-$24.59M
Year ended 2025-12-31
-$17.30M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$24.59M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$33.54M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$28.32M | n/m | 2025-04-03, From 2023-01-01 |
| 2022-12-31 | -$18.96M | n/m | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | -$10.67M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$4.07M | n/c | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$218.4K | n/a | 2021-05-07, From 2019-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | -$24.59M | n/m |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | -$12.89M | n/m |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | -$7.17M | n/m |
| Synlogic, Inc. (SYBX) | 2025-12-31 | -$4.36M | n/m |
| Aditxt, Inc. (ADTX) | 2025-12-31 | -$25.69M | n/m |
| Cingulate Inc. (CING) | 2025-12-31 | -$17.25M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | -$23.12M | n/m |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | -$26.82M | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$9.76M | n/m |
Compare RVPH, APRE, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗